drugset / Trial / NCT05711940
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)
Timeline
- Start
- 2023-02-14
- Primary completion
- 2026-02
- Completion
- 2026-12
Outcome
Met primary endpoint
release “announced today the successful achievement of the primary endpoint in the ongoing Phase 3 COMP006 trial, the second of two Phase 3 trials” compasspathways.com ↗
release “Data from positive COMP006 Phase 3 trial demonstrates durable benefit through at least 6 months” compasspathways.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Psilocybin | Other / unclassified | 1 mg | — |
| Subject | Psilocybin | Other / unclassified | 10 mg | — |
| Subject | Psilocybin | Other / unclassified | 25 mg | — |
Indications
No indication recorded.